Respitose ML006 (DMV-Fonterra)
Phase 2Small molecule
Respitose ML006 (DMV-Fonterra) is one of 56 small molecule programs targeting Bronchiectasis. It is currently in Phase 2.
2
Indications
2
Total Trials
0
Active Trials
55
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
1053 competitors in Influenza
#DrugCompanyPhaseTrials
1Fluzone
SanofiPreclinical
Crestor
AstraZenecaPreclinical
Trexall
Alnylam PharmaceuticalsPreclinical
Avigan
AAppili Therapeutics Inc.
Preclinical
Quadrivalent Influenza Vaccine
SanofiPreclinical
Respitose ML006 (DMV-Fonterra)
AAnsun Biopharma, Inc.
Phase 2
COMIRNATY
PfizerPreclinical
Influenza A/H5N1
NNational Institute of Allergy and Infectious Diseases (NIAID)
Preclinical
PD-1/PD-L1 Inhibitors
CChuangzhen Chen
Preclinical
Fluvirin
NovartisPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- AAnsun Biopharma, Inc.